Volume 57, Issue 3, Pages (March 2000)

Slides:



Advertisements
Similar presentations
Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.
Advertisements

Navdeep Tangri, Paul V.J. Komenda, Claudio Rigatto 
Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants  C.A. Solid,
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction 
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Shining light on vitamin D trials in chronic kidney disease
Volume 80, Issue 10, Pages (November 2011)
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 81, Issue 4, Pages (February 2012)
Audit-based education: a potentially effective program for improving guideline achievement in CKD patients  Moniek C.M. de Goeij, Joris I. Rotmans  Kidney.
Volume 85, Issue 3, Pages (March 2014)
Salt and Hypertension American Journal of Kidney Diseases
Is there a pharmacologic basis for combination renin axis blockade?
Ian H. de Boer, Rajnish Mehrotra  Kidney International 
Volume 72, Issue 6, Pages (September 2007)
Volume 72, Issue 2, Pages (July 2007)
Comorbidity and confounding in end-stage renal disease
Volume 74, Issue 3, Pages (August 2008)
The new role of calcimimetics as vasculotropic agents
Volume 16, Issue 5, Pages (May 1996)
Volume 70, Issue 11, Pages (December 2006)
Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension  A. Davenport, C. Cox, R. Thuraisingham  Kidney.
Harnessing regulatory T cells for therapeutic purposes
Bisphosphonate safety and efficacy in chronic kidney disease
Volume 71, Issue 6, Pages (March 2007)
Volume 70, Issue 12, Pages (December 2006)
Kenar D. Jhaveri, Steven Fishbane  Kidney International 
Blood pressure targets in hemodialysis patients
Volume 76, Issue 5, Pages (September 2009)
Fructose intake as a risk factor for kidney stone disease
Progression of polycystic kidney disease in a kidney transplant
Renal and vascular actions of urotensin II
Navdeep Tangri, Paul V.J. Komenda, Claudio Rigatto 
Extracorporeal therapy in sepsis: are we there yet?
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Presentation of the 2003 Jean Hamburger Award to Robert W. Schrier
Methods for guideline development
Volume 87, Issue 1, Pages (January 2015)
The global challenge of chronic kidney disease
Nephrology Crossword: Glomerulonephritis
Volume 57, Issue 3, Pages (March 2000)
Hydrogen: another gas with therapeutic potential
Volume 82, Issue 7, Pages (October 2012)
Leptin and inflammation-associated cachexia in chronic kidney disease
Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants  C.A. Solid,
Hemodialysis with high-calcium dialysate impairs cardiac relaxation
Volume 73, Issue 5, Pages (March 2008)
Organ transplantation goes to the movies
Atherosclerotic nephropathy
The vascular secret of Klotho
Volume 80, Issue 10, Pages (November 2011)
Volume 82, Issue 6, Pages (September 2012)
Is it the low-protein diet or simply the salt restriction?
This Month in AJKD American Journal of Kidney Diseases
Charles A. Herzog  Kidney International 
Is complement a target for therapy in renal disease?
Urinalysis in Western culture: A brief history
Volume 70, Issue 3, Pages (August 2006)
Volume 71, Issue 9, Pages (May 2007)
Volume 72, Issue 11, Pages (December 2007)
Aldosterone and potassium secretion by the cortical collecting duct
Hisataka Kobayashi, Peter L. Choyke  Kidney International 
T cells and T-cell receptors in acute renal failure
Volume 70, Issue 10, Pages (November 2006)
Tissue protection by erythropoietin: new findings in a moving field
Volume 74, Issue 10, Pages (November 2008)
Systems Biophysics: Multiscale Biophysical Modeling of Organ Systems
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Presentation transcript:

Volume 57, Issue 3, Pages 838-845 (March 2000) Potassium channel openers as potential therapeutic weapons in ion channel disease  Kim Lawson  Kidney International  Volume 57, Issue 3, Pages 838-845 (March 2000) DOI: 10.1046/j.1523-1755.2000.00923.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Chemical structures of potassium ATP-sensitive K+ channel openers (KATPCOs). Kidney International 2000 57, 838-845DOI: (10.1046/j.1523-1755.2000.00923.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Heterogeneous pharmacology of KATPCOs. Activation of KATP channels by those agents is indicated by check marks, and no or very little effect is indicated by x. Kidney International 2000 57, 838-845DOI: (10.1046/j.1523-1755.2000.00923.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Tissue selective KATPCOs. Compounds combining the structural features of cromakalim and pinacidil have allowed the uncoupling of vascular smooth muscle relaxation from the cardiac actions of these KATPCOs. Kidney International 2000 57, 838-845DOI: (10.1046/j.1523-1755.2000.00923.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 KATPCO pharmacology of the sulphonylurea receptor (SUR) isoforms. Activation of the KATP channel formed from expressed Kir6.2 and the SUR isoform shown is indicated by D, P, C and N for diazoxide, pinacidil, cromakalim and nicorandil, respectively. Percentage values respresent the identity levels of the different SUR isoforms. Kidney International 2000 57, 838-845DOI: (10.1046/j.1523-1755.2000.00923.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 5 Therapeutic targets for KATPCOs. Preclinical and limited clinical studies have demonstrated effects for one or more of the KATPCOs in a broad spectrum of tissues. SUR isoforms are indicated where they represent the target for the KATPCOs. Kidney International 2000 57, 838-845DOI: (10.1046/j.1523-1755.2000.00923.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 6 Chemical structures of small molecule high conductance Ca2+-activated K+ channel openers (BKCaCOs). Kidney International 2000 57, 838-845DOI: (10.1046/j.1523-1755.2000.00923.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 7 Chemical structures of natural product BKCa COs. Kidney International 2000 57, 838-845DOI: (10.1046/j.1523-1755.2000.00923.x) Copyright © 2000 International Society of Nephrology Terms and Conditions